A phase I study of 17-dimethlyaminoethylamino-17-demethoxygeldanamycin (17-DMAG) (NSC 707545) [alvespimycin] in patients with advanced solid tumors

Trial Profile

A phase I study of 17-dimethlyaminoethylamino-17-demethoxygeldanamycin (17-DMAG) (NSC 707545) [alvespimycin] in patients with advanced solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Alvespimycin (Primary)
  • Indications Anaplastic large cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; MALT lymphoma; Mantle-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Solid tumours; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 15 Jun 2010 Actual end date (1 Jun 2010) added as reported by ClinicalTrials.gov.
    • 15 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Planned number of patients changed from 3 to 60 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top